The Ovarian Cancer Research Alliance has honored Dr. David Gershenson, with the Rosalind Franklin Prize for Excellence in Ovarian Cancer Research, recognizing his groundbreaking contributions to ovarian cancer research.

A leader in the study of rare ovarian cancers, Dr. David Gershenson has significantly advanced understanding and treatment of low-grade serous carcinoma. His extensive contributions to ovarian cancer research continue to shape the future of treatment and care for patients worldwide.

Congratulations, Dr. David Gershenson, on this well-deserved recognition!

The ICLC put on their dancing shoes on February 8, 2025 for the Dancing with the STAAR’s event at the inaugural LGSOC Patient Conference. It was a night to remember as attendees dressed up for an evening filled with dinner, dancing, and heartfelt celebration, honoring STAAR’s 5-year milestone and the incredible STAAR’s who inspire us every day.

This special event brought together patients, caregivers, advocates, and supporters, creating a powerful sense of community and hope.

The STAAR Low-Grade Serous Ovarian Cancer Foundation is hosting a conference to unite LGSOC patients for the first time, aiming to foster community and address the unique challenges and recent research advancements related to this rare cancer. This two-day event is scheduled for February 7-8, 2025, in Houston, Texas.

This Event Highlights the Impactful Work of Our ICLC Members:

State of LGSOC by Dr. David Gershenson, The University of Texas MD Anderson Cancer Center

What Happens in an LGSOC Lab? by Dr. Kwong K. Wong, The University of Texas MD Anderson Cancer Center

LGSOC Research Timeline: What Is on the Horizon? by Dr. Brian Slomovitz, Mount Sinai Medical Center

Understanding Clinical Trials by Dr. Rachel Grisham, Memorial Sloan Kettering Cancer Center

Understanding Recurrence by Dr. Lauren Cobb, The University of Texas MD Anderson Cancer Center

ICLC Member’s, Drs. Kwong K. Wong and Dr. Anil Sood participated in fundraising for Ovarcome at the Chevron Houston Marathon on January 11, 2025.

Each step they took was a step toward hope, awareness, and a future free of ovarian cancer.

Here’s to more progress, more breakthroughs, and more Ovarcoming!

As the organization has expanded and developed, it has remained committed to its fundamental values and mission. It continues to back LGSOC research in Australia, Canada, the United Kingdom, the United States, and New Zealand.

On the inaugural World Low-Grade Serous Ovarian Cancer Day, the organization revealed that its global LGSOC efforts will be rebranded as the Low-Grade Serous Ovarian Cancer Initiative, alongside the launch of its redesigned website. This new designation signifies their steadfast commitment to the LGSOC community across the globe.

Their mission is to significantly improve survival rates for women with low-grade serous ovarian cancer through research and to provide reliable information that empowers them to make informed decisions about their care.